In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment

Anti-Cancer Drugs

Volumn 16, Issue 4, 2005, Pages 417-422

  Cabrespine, Aurélie ^a,b   Bay, Jacques Olivier ^b   Barthomeuf, Chantal ^a,c   Curé, Hervé ^a,b   Chollet, Philippe ^a,b   Debiton, Eric ^a,c  

^a INSERM   (France)

^b CENTRE JEAN PERRIN   (France)

^c Faculte de Pharmacie   (France)

Author keywords

Additivity; Cytotoxic agents; Median effect analysis; Prostate cancer cell lines; Synergism

Indexed keywords

CARBOPLATIN; CHELERYTHRINE; CYTOTOXIC AGENT; DIMETHYL SULFOXIDE; DNA; HOE 33342; ISOTRETINOIN; MITOXANTRONE; PACLITAXEL; RESAZURIN; RESORUFIN;

ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL METABOLISM; CONTROLLED STUDY; DNA DETERMINATION; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG POTENTIATION; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROSTATE CANCER;

ALKALOIDS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOPHENANTHRIDINES; CARBOPLATIN; DRUG ANTAGONISM; DRUG SYNERGISM; HUMANS; ISOTRETINOIN; MALE; MITOXANTRONE; NEOPLASMS, HORMONE-DEPENDENT; PACLITAXEL; PHENANTHRIDINES; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 15944415455     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200504000-00008     Document Type: Article

References (36)

1. Dennis LK, Resnick MI. Analysis of recent trends in prostate cancer incidence and mortality. Prostate 2000; 42: 247-252.
2. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17:2506-2513.
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
4. Trivedi C, Redman B, Flaherty LE, Kucuk O, Du W, Heilbrun LK, et al. Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer 2000; 89:431-436.
5. Canobbio L, Guarneri D, Miglietta L, Decensi A, Oneto F, Boccardo F. Carboplatin in advanced hormone refractory prostatic cancer patients. Eur J Cancer 1993; 29:2094-2096.
6. Herbert JM, Augereau JM, Gleye J, Maffrand JP. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 1990; 172:993-999.
7. Hammond LA, Brown G, Keedwell RG, Durham J, Chandraratna RAS. The prospects of retinoids in the treatment of prostate cancer. Anticancer Drugs 2002; 13:781-790.
8. Chou TC, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menton and higher order kinetic systems with two or more mutually exclusive and non-exclusive inhibitors. Eur J Biochem 1981; 115:207-216.
9. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enz Reg 1984; 22:27-55.
10. Debiton E, Madelmont JC, Legault J, Barthomeuf C. Sanguinarine-induced apoptosis is associated with an early and severe cellular glutathione depletion. Cancer Chemother Pharmacol 2003; 51: 474-482.
11. De Lean A, Munson PJ, Guardabasso V, Rodbard D. User's guide to ALLFIT. Bethesda, MD: NIH; 1988.
12. Chou TC. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 1976; 7:253-276.
13. Budman DR, Calabro A, Kreis W. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs 2002; 13:1011-1016.
14. Chou TC, Hayball MP. CalcuSyn. Cambridge: Biosoft; 1996.
15. Zoli W, Ricotti L, Tesei A, Barzanti F, Amadori D. In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. Crit Rev Oncol Hematol 2001; 37:69-82.
16. Zhang XK. Vitamins A and apoptosis in prostate cancer. Endocr Relat Cancer 2002; 9:87-102.
17. DiPaola RS, Aisner J. Overcoming bcl-2 and p53 mediated resistance in prostate cancer. Semin Oncol 1999; 26:112-116.
18. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56: 1253-1255.
19. Zhang C, DiPaola R, White E, Hait WN. Restoration of Taxol sensibility in a p53 mutant, bcl-2 overexpressing cell line by interferon-α and retinoic acid. Proc Am Ass Cancer Res 1997; 38:abstr 3563.
20. Thalasila A, Poplin E, Shih J, Dvorzhinski D, Capanna T, Doyle-Lindrud S, et al. A phase I trial of weekly paclitaxel, 13-cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies. Cancer Chemother Pharmacol 2003; 52:119-124.
21. Engblom P, Rantanen V, Kulmala J, Grénman S. Carboplatin- paclitaxel and carboplatin-docetaxel induced cytotoxic effect in epithelial ovarian carcinoma in vitro. Cancer 1999; 86:2066-2073.
22. Ozols RE Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Semin Oncol 1995; 22:1 -6.
23. Urakami S, Igawa M, Kikuno N, Yoshino T, Kishi H, Shigeno K, et al. Combination chemotherapy with, paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 2002; 168:2444-2450.
24. Speicher LA, Barone L, Tew KD. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 1992; 52:4433-4440.
25. Obasaju CK, Johnson SW, Rogatko A, Kilpatrick D, Brennan JM, Hamilton TC, et al. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin Cancer Res 1996; 2:549-552.
26. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (Taxol) and docetaxel (Taxotere). Int J Cancer 2003; 104:121-129.
27. Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003; 14:13-19.
28. Grant S, Jarvis WD. Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy. Clin Cancer Res 1996; 2:1915-1920.
29. Deacon EM, Pongracz J, Griffith G, Lord JM. Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis. J Clin Pathol: Mol Pathol 1997; 50:124-131.
30. Orlandi L, Binda M, Foloni M, Bearzatto A, Villa R, Daidone MG, et al. Ribozyme-mediated inhibition of PKCα sensitizes androgen-independent human prostate cancer cells to cisplatin-induced apoptosis. Prostate 2004; 54:133-143.
31. Hudes GR. (2002) Signaling inhibitors in the treatment of prostate cancer. Invest New Drugs 2002; 20:159-173.
32. Hofmann J. Modulation of protein kinase C in antitumor treatment. Rev Physiol Biochem Pharmacol 2001; 142:1-96.
33. L function. J Biol Chem. 2003; 278:20453-20456.
34. L in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res 2000; 60:6052-6060.
35. L mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells. J Biol Chem 2003; 28: 25872-25878.
36. Hoffmann TK, Leenen K, Hafner D, Balz V, Gerharz CD, Grund A, et al. Antitumor activity of protein kinase C inhibitors and cisplatin in human head and neck squamous cell carcinoma lines. Anticancer Drugs 2002; 13:93-100.